. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: Urol Oncol. 2021 Jan 23;39(7):437.e1–437.e9. doi: 10.1016/j.urolonc.2021.01.006

Table 3b.

Univariate and multivariable Cox models for overall survival by GU malignancy subtype, age, gender, comorbidity index, number of immune-mediated allergies, and sites of metastases.

Variable	Description	Univariate Hazard Ratio (95% CI)	p-value	Multivariable Hazard Ratio (95% CI)	p-value
GU Malignancy Subtype	Urothelial vs RCC	2.08 (1.32, 3.26)	0.0015^*	2.61 (1.55, 4.39)	0.0003^*
Age	per 10 years	1.18 (0.96, 1.45)	0.12	0.99 (0.79, 1.26)	0.95
Gender	Male vs Female	0.81 (0.51, 1.28)	0.36	0.77 (0.48, 1.25)	0.29
NCI Comorbidity Index	0.01–2 vs 0	0.69 (0.39, 1.23)	0.21	0.70 (0.38, 1.27)	0.24
NCI Comorbidity Index	>2 vs 0	1.36 (0.81, 2.28)	0.25	1.73 (0.99, 3.02)	0.054
Number of Allergies	1 vs 0	0.92 (0.55, 1.55)	0.76	0.95 (0.55, 1.64)	0.85
Number of Allergies	≥2 vs 0	0.91 (0.53, 1.57)	0.73	0.88 (0.48, 1.62)	0.69
Site of Metastases	Liver vs LN only	2.48 (1.37, 4.50)	0.0028^*	3.12 (1.66, 5.87)	0.0004^*
	Liver vs Lung	2.97 (1.43, 6.16)	0.0034^*	3.77 (1.76, 8.08)	0.0007^*
	Liver vs CNS/Bone	2.06 (1.06, 4.00)	0.0340^*	2.06 (1.03, 4.15)	0.0420^*

Statistically significant

GU = genitourinary; RCC = renal cell carcinoma; CNS = central nervous system; LN = lymph node